Inactive Instrument

Impax Laboratories Inc Stock Nasdaq

Equities

US45256B1017

Pharmaceuticals

Sales 2024 * 2.6B Sales 2025 * 2.73B Capitalization 1.82B
Net income 2024 * 14M Net income 2025 * 22M EV / Sales 2024 * 1.58 x
Net Debt 2024 * 2.29B Net Debt 2025 * 2.07B EV / Sales 2025 * 1.43 x
P/E ratio 2024 *
118 x
P/E ratio 2025 *
65.6 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 24.26%
More Fundamentals * Assessed data
Dynamic Chart
Amneal Pharmaceuticals Cleared by FDA to Sell Generic Version of Nasal Spray to Treat Opioid Overdose -- Shares Rise MT
Amneal Pharmaceuticals Shares Rise 9% After FDA Approves Naloxone Spray DJ
Amneal Announces U.S. FDA Approval of Over-The-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose CI
Shilpa Medicare Partner Amneal Pharma Launches Ready-to-Use Pemetrexed in US MT
Amneal Pharmaceuticals Announces Launch of Pemetrexed Injection, 100mg/10 Mg/10 Mg/50 Mg/Ll CI
Bausch Health Gets 'Positive' Court Ruling on Xifaxan With Market Odds of Bausch + Lomb Distribution at 32%, RBC Says MT
RBC Notes "Positive" Appellate Court Ruling For Bausch Health, But Thinks Market Assigning ~32% BLCO Distribution Odds MT
TSX ends flat as gold stocks drop, mood cautious ahead of rate decision RE
Bausch Health Up Near 0.4% In US Premarket After Announcing Patent Lawsuit Against Amneal Pharmaceuticals MT
North American Morning Briefing : Inflation Data, -2- DJ
Amneal Pharma Gets FDA Nod for Infection Fighting Drug Combination DJ
Amneal Pharmaceuticals Receives FDA Approval for Ear Infection Treatment MT
Amneal Pharmaceuticals, Inc Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension CI
Transcript : Amneal Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 08:30 AM
Goldman Sachs Adjusts Price Target on Amneal Pharmaceuticals to $6.25 From $5.50, Maintains Buy Rating MT
More news
Managers TitleAgeSince
Founder 57 01-12-31
Founder 53 01-12-31
Director of Finance/CFO 57 Nov. 06
Members of the board TitleAgeSince
Director/Board Member 66 Nov. 06
Director/Board Member 69 Nov. 06
Chairman 71 Nov. 06
More insiders
Amneal Pharmaceuticals, Inc., is a fully integrated global essential medicine company. The Company is engaged in the development, manufacturing, and distribution of a diverse portfolio of approximately 270 pharmaceutical products, primarily within the United States. The Company’s Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermal across a broad range of therapeutic categories. The Company's Specialty segment’s portfolio includes central nervous system disorders (Parkinson’s disease, spasticity, migraine), endocrinology (hypothyroidism), and other therapeutic areas. The Company’s AvKARE segment provides pharmaceuticals, medical and surgical products, and services to government, retail, and institutional markets.
Calendar
Related indices
More about the company